Nektar Therapeutics (NKTR) Shares Outstanding (2010 - 2026)

Nektar Therapeutics' Shares Outstanding (Entity) history runs 17 years deep, the most recent figure standing at $29.5 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 127.41% year-over-year to $29.5 million in Q1 2026; TTM through Mar 2026 was $29.5 million, a 127.41% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 30.4% from the prior year.
• Shares Outstanding (Entity) rose to $29.5 million in Q1 2026 per NKTR's latest filing, from $16.9 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $29.5 million in Q1 2026 and bottomed at $12.4 million in Q1 2022.
• The 5-year median for Shares Outstanding (Entity) is $12.8 million (2024), against an average of $14.4 million.
• Across the five-year window, Shares Outstanding (Entity) increased 1.03% in 2024 and soared 127.41% in 2026, its largest moves.
• Year by year, Shares Outstanding (Entity) stood at $12.6 million in 2022, then grew by 1.5% to $12.8 million in 2023, then rose by 1.4% to $12.9 million in 2024, then surged by 30.4% to $16.9 million in 2025, then jumped by 74.69% to $29.5 million in 2026.
• Per Business Quant, the three latest NKTR Shares Outstanding (Entity) figures stand at $29.5 million (Q1 2026), $16.9 million (Q4 2025), and $19.7 million (Q3 2025).